Unknown

Dataset Information

0

Radiosensitization of gliomas by intracellular generation of 5-fluorouracil potentiates prodrug activator gene therapy with a retroviral replicating vector.


ABSTRACT: A tumor-selective non-lytic retroviral replicating vector (RRV), Toca 511, and an extended-release formulation of 5-fluorocytosine (5-FC), Toca FC, are currently being evaluated in clinical trials in patients with recurrent high-grade glioma (NCT01156584, NCT01470794 and NCT01985256). Tumor-selective propagation of this RRV enables highly efficient transduction of glioma cells with cytosine deaminase (CD), which serves as a prodrug activator for conversion of the anti-fungal prodrug 5-FC to the anti-cancer drug 5-fluorouracil (5-FU) directly within the infected cells. We investigated whether, in addition to its direct cytotoxic effects, 5-FU generated intracellularly by RRV-mediated CD/5-FC prodrug activator gene therapy could also act as a radiosensitizing agent. Efficient transduction by RRV and expression of CD were confirmed in the highly aggressive, radioresistant human glioblastoma cell line U87EGFRvIII and its parental cell line U87MG (U87). RRV-transduced cells showed significant radiosensitization even after transient exposure to 5-FC. This was confirmed both in vitro by a clonogenic colony survival assay and in vivo by bioluminescence imaging analysis. These results provide a convincing rationale for development of tumor-targeted radiosensitization strategies utilizing the tumor-selective replicative capability of RRV, and incorporation of radiation therapy into future clinical trials evaluating Toca 511 and Toca FC in brain tumor patients.

SUBMITTER: Takahashi M 

PROVIDER: S-EPMC4246057 | biostudies-literature | 2014 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Radiosensitization of gliomas by intracellular generation of 5-fluorouracil potentiates prodrug activator gene therapy with a retroviral replicating vector.

Takahashi Masamichi M   Valdes Gilmer G   Hiraoka Kei K   Inagaki Akihito A   Kamijima Shuichi S   Micewicz Ewa E   Gruber Harry E HE   Robbins Joan M JM   Jolly Douglas J DJ   McBride William H WH   Iwamoto Keisuke S KS   Kasahara Noriyuki N  

Cancer gene therapy 20141010 10


A tumor-selective non-lytic retroviral replicating vector (RRV), Toca 511, and an extended-release formulation of 5-fluorocytosine (5-FC), Toca FC, are currently being evaluated in clinical trials in patients with recurrent high-grade glioma (NCT01156584, NCT01470794 and NCT01985256). Tumor-selective propagation of this RRV enables highly efficient transduction of glioma cells with cytosine deaminase (CD), which serves as a prodrug activator for conversion of the anti-fungal prodrug 5-FC to the  ...[more]

Similar Datasets

| S-EPMC4218156 | biostudies-literature
| S-EPMC7073086 | biostudies-literature
| S-EPMC3266384 | biostudies-literature
| S-EPMC6422008 | biostudies-literature
| S-EPMC4761857 | biostudies-literature
| S-EPMC7197216 | biostudies-literature
| S-EPMC6481342 | biostudies-literature
| S-EPMC5363416 | biostudies-literature
| 2200169 | ecrin-mdr-crc
| S-EPMC5751967 | biostudies-literature